Novartis Challenges Gleevec Patent Block In India

Law360, New York (August 14, 2006, 12:00 AM EDT) -- Less than a year after India’s Patent Controller denied Novartis AG's patent application for the cancer treatment Gleevec, the Swiss-based pharmaceutical company is railing against the rejection.

Novartis recently filed multiple writs at the Madras High Court against the Patent Controller's decision to reject its patent application and is also seeking an interim stay, the Hindu Business Line reported this week.

The Chennai Patent Office rejected Novartis’ application in January on the grounds that Gleevec was not significantly different in properties from an already existing compound....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.